Erythrocytes in Human Blood Under EMF Conditions — Tarlykov (2024)

By P.V. Tarlykov

2024 — Most Recent Researcher: P.V. Tarlykov Cluster: Blood & Biological Method: Hematological Analysis Follow-On Study

Study Overview

This 2024 study by P.V. Tarlykov is a follow-on to the same researcher’s 2019 erythrocyte research, applying updated methodology and current-generation Aires device configurations to the question of EMF effects on red blood cells in human blood. The five-year interval between studies allows assessment of whether the effects identified in 2019 persist across device generations and measurement refinements.

As the most recent blood biology study in the Aires research program, this work represents the current state of cellular-level evidence. It is also notable as one of the few instances in the program where a single researcher has returned to the same research question over multiple years, providing longitudinal consistency evidence within a single investigator’s work.

Relationship to the 2019 Study

2019 Study

Initial investigation. Established erythrocyte parameters as a viable EMF effect measure. First observation of Aires resonator’s effect on cellular-level blood indicators.

2024 Study

Follow-on investigation. Updated measurement methodology. Current-generation Aires device. Tests durability of 2019 findings across a five-year interval and device evolution.

This study was commissioned by the Aires Human Genome Research Foundation but conducted independently. The Foundation provided test devices and research parameters; methodology, data collection, and conclusions were controlled entirely by the researcher.

Key Findings

Finding 1 — EMF Effect on Erythrocytes Confirmed (2024) The 2024 study confirms that EMF exposure continues to produce measurable changes in erythrocyte state, consistent with the 2019 findings. The persistence of this effect across a five-year interval, during which ambient device EMF environments have changed substantially (4G to 5G transition, increased device density), indicates the effect is robust to environmental variation.
Finding 2 — Current-Generation Aires Device Effective The current-generation Aires device (as tested in 2024) produced erythrocyte parameter attenuation consistent with the 2019 findings using earlier device generations. This is significant: it demonstrates that the technology’s biological effect is maintained as the product evolves, which would not be guaranteed if the effect were dependent on specific manufacturing parameters rather than the underlying fractal diffraction principle.
Finding 3 — Five-Year Longitudinal Consistency The consistency of erythrocyte findings between 2019 and 2024 — same researcher, same research question, same directional results — provides longitudinal stability evidence that is rare in the EMF biological effects literature. Most studies are conducted once; returning to the same question five years later with the same researcher produces a different and stronger form of evidence.

Scientific Context

The 2024 study exists in a research landscape that has changed significantly since 2013, when the first HRV and water structure studies were conducted. 5G network infrastructure has been partially deployed in many regions, increasing the frequency range and density of ambient electromagnetic fields in daily environments. The fact that erythrocyte effects remain measurable and Aires attenuation remains observable in this changed environment is relevant to the technology’s real-world applicability.

Together, the 2019 and 2024 Tarlykov studies form the complete blood biology component of the Aires research archive, complementing the neurological (EEG), cardiovascular (HRV), and water structure research clusters with a distinct cellular-level evidence domain.

Related Research

Researcher Profile: P.V. Tarlykov Blood & Biological Cluster ← All Research

Tags: 2024, Biological Effects, Blood, EMF Research, Erythrocytes, Independent Study, Peer Reviewed